| scholarly article | Q13442814 |
| P2093 | author name string | Jay I Goodman | |
| P2860 | cites work | IPCS framework for analyzing the relevance of a cancer mode of action for humans. | Q53587174 |
| Anticarcinogenic responses in rodent cancer bioassays are not explained by random effects | Q74658454 | ||
| Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? | Q81376834 | ||
| Chemical carcinogenesis | Q82836038 | ||
| Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary | Q83161176 | ||
| Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009) | Q83935535 | ||
| Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection | Q24564216 | ||
| Issues in carcinogenicity testing: dose selection | Q30406737 | ||
| Prediction of carcinogenic potential of chemicals using repeated-dose (13-week) toxicity data | Q31129161 | ||
| Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator | Q33606444 | ||
| Chemical carcinogenesis: too many rodent carcinogens | Q33830472 | ||
| Percivall Pott (1714-1788) and chimney sweepers' cancer of the scrotum | Q33969386 | ||
| Altered DNA methylation: a secondary mechanism involved in carcinogenesis | Q34504084 | ||
| The traditional toxicologic paradigm is correct: dose influences mechanism | Q34940462 | ||
| Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents | Q35034198 | ||
| Long-term chemical carcinogenesis experiments for identifying potential human cancer hazards: collective database of the National Cancer Institute and National Toxicology Program (1976-1991) | Q35034726 | ||
| Best-estimate low-dose extrapolation of carcinogenicity data | Q35132430 | ||
| Dose-dependent transitions in mechanisms of toxicity | Q35975273 | ||
| Dose-dependent transitions in mechanisms of toxicity: case studies | Q35975278 | ||
| Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host | Q36257990 | ||
| Genetic errors, cell proliferation, and carcinogenesis | Q36788143 | ||
| Analysis of National Toxicology Program rodent bioassay data for anticarcinogenic effects | Q36802200 | ||
| Too many rodent carcinogens: mitogenesis increases mutagenesis | Q37848515 | ||
| Cell proliferation in carcinogenesis | Q37951208 | ||
| Muller's Nobel Prize Lecture: when ideology prevailed over science | Q37968101 | ||
| Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans | Q38129673 | ||
| Human relevance framework for rodent liver tumors induced by the insecticide sulfoxaflor | Q38212105 | ||
| Flaws in the LNT single-hit model for cancer risk: An historical assessment | Q38653653 | ||
| Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties | Q38818082 | ||
| Influence of DNA repair on nonlinear dose-responses for mutation | Q39216690 | ||
| Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism | Q40371097 | ||
| Alterations in DNA methylation may play a variety of roles in carcinogenesis | Q40410595 | ||
| Historical review of the rodent bioassay and future directions | Q40546962 | ||
| A rational approach to risk assessment requires the use of biological information: an analysis of the National Toxicology Program (NTP), final report of the advisory review by the NTP Board of Scientific Counselors | Q40741242 | ||
| Alternatives to the 2-species bioassay for the identification of potential human carcinogens | Q41137398 | ||
| Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP | Q43717333 | ||
| Cancer risk assessment approaches at the FDA/CDER: Is the era of the 2-year bioassay drawing to a close? | Q43734471 | ||
| Evaluating the human relevance of chemically induced animal tumors | Q47250065 | ||
| Weight and survival depression in rodent bioassays with and without tumor decreases | Q47287024 | ||
| The rodent carcinogenicity bioassay produces a similar frequency of tumor increases and decreases: implications for risk assessment | Q50146519 | ||
| An integrative test strategy for cancer hazard identification. | Q50856445 | ||
| An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. | Q51559026 | ||
| Carcinogen testing: current problems and new approaches. | Q53569528 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 558-564 | |
| P577 | publication date | 2018-02-06 | |
| P1433 | published in | Toxicology research | Q26853990 |
| P1476 | title | Goodbye to the bioassay. | |
| P478 | volume | 7 |
| Q100509843 | A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals |
| Q91950350 | Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment |
| Q99560130 | Quantification of Cancer Driver Mutations in Human Breast and Lung DNA Using Targeted, Error-corrected CarcSeq |
Search more.